# Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

> **NCT04975919** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine and Cedazuridine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04975919
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-29
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975919, "Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT04975919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*